Prostate-specific antigen (PSA) testing may not accurately pinpoint levels at which transgender women on estrogen therapy may be at risk of developing prostate cancer, according to data from the ...

Screening PSA levels at aged 65-69 may inform the decision to continue or discontinue prostate cancer screening after age 70 years, regardless of patient race and ethnicity. The absolute risks of ...

An initiative is aimed at encouraging physicians to consider abnormal PSA values in a broader context. About two years ago, having recognized that the prostate-specific antigen (PSA) cutoff level of 4 ...